TNK2 Inhibitor (R)-9bMS Causes Polyploidization Through Mitotic Failure by Targeting Aurora B

Area of Science:

• Oncology
• Cell Biology
• Biochemistry

Background:

• TNK2 (tyrosine kinase) is implicated in tumorigenesis and is a target for cancer chemotherapy.
• TNK2 inhibitors, like XMD16-5, can inhibit cytokinesis by targeting Aurora B kinase at higher concentrations.
• Cytokinesis failure leads to polyploid cells, which can drive cancer development and progression.

Purpose of the Study:

• To investigate if the TNK2 inhibitor (R)-9bMS promotes malignant progression by inducing abnormal cell division.
• To examine the effects of (R)-9bMS on cell division, Aurora B autophosphorylation, and colony formation.

Main Methods:

• Cell counting and microscopic observation of cancer cell lines (A431, HeLa S3, HCT116, MCF7).
• Flow cytometry to assess DNA content and centrosome numbers.
• Time-lapse imaging to analyze mitotic events.
• TNK2 knockdown experiments.

Main Results:

• (R)-9bMS treatment reduced cell numbers and induced multinucleated, enlarged cells with increased DNA content and centrosomes.
• Mitotic failure, including slippage and cytokinesis failure, caused polyploidization.
• TNK2 knockdown had a limited effect on multinucleated cells, while (R)-9bMS reduced Aurora B phosphorylation.
• (R)-9bMS promoted anchorage-independent colony formation, a cancer hallmark.

Conclusions:

• TNK2 inhibitors (R)-9bMS and XMD16-5 induce polyploidization via Aurora B kinase inhibition, not direct TNK2 inhibition.
• High concentrations of (R)-9bMS may promote cancer development and malignant progression.
• Caution is advised when using TNK2 inhibitors for cancers not driven by TNK2 mutations, especially at higher doses.